Published in Physician Law Weekly, August 15th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GPC Biotech AG.
Report 1: GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) announced that the Company has been informed by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for satraplatin for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed will be reviewed by the Oncologic Drugs Advisory Committee (ODAC) on July 24, 2007. Advisory committees provide the FDA with independent advice from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.